Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-27T21:17:33.898Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of clozapine in a mental handicap hospital — report of the first 17 patients

Published online by Cambridge University Press:  13 June 2014

Ahmed Boachie  and
Maria GA McGinnity
Ahmed Boachie
Affiliation:
Department of Child Psychiatry, The Royal Belfast Hospital for Sick Children (RBHSC), Falls Road, Belfast BT12, Northern Ireland
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: To examine the process and outcome of use of clozapine in patients with mental handicap, with particular reference to selection of patients, response to treatment, adverse effects and withdrawal from treatment.

Methods: The case notes and medication charts of all patients commenced on clozapine between January 1991 and December 1994 were examined.

Results: Seventeen patients had been commenced on clozapine, the majority in the mild and moderate range of handicap. Fifteen had ICD-9 diagnosis of schizophrenia and all were refractory to conventional neuroleptics. Improvement was marked in 47% and substantial in 76%, with a mean daily dose of 453.8(sd = 238.5)mg and a range of 200mg-900mg. Reduction of aggressive behaviour was an important indicator of improvement. Five patients were withdrawn but only one related to side effects. Four patients had a past history of epilepsy and six others either developed seizures or EEG changes on treatment.

Conclusion: Clozapine use has been associated with considerable benefit in patients with mild and moderate handicap wh o have schizophrenia. In this population aggression responded well but a high prevalence of drug-induced epilepsy was evident.

Keywords

Mental handicapClozapineEpilepsyAggression
Type
Brief Reports
Information
Irish Journal of Psychological Medicine , Volume 14 , Issue 1 , March 1997 , pp. 16 - 19
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Clozapine study group. The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psychiatry 1993; 163: 150–4.CrossRefGoogle Scholar
2.Cohen, S, William, S, Sulzbacher, , Sharnar, K. The use of clozapine in an institutionalised population with mental retardation. Neuropsychopharmacology 1993;9:1185–95.Google Scholar
3.Sajatovic, M, Ramirez, LF, Kenny, TJ, Melter, YH. The use of clozapine in borderline intellectual functioning and mentally retarded schizophrenic patients. Compr Psychiatry 1994; 35: 29–33.CrossRefGoogle ScholarPubMed
4.Hemphill, RE, Pascoe, FD, Zabow, T. An investigation of use of clozapine in the treatment of acute and chronic schizophrenia and gross behaviour disorders. S Afr Med J 1975; 49: 2121–5.Google ScholarPubMed
5.Michelis, ML, Maculas, , Crimson, ML, Roberts, S, Childs, A. Clozapine response and adverse effects in nine brain-injured patients J Clin Psychopharmacol 1993; 13: 198–203.Google Scholar
6.Davis, JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1994; 11:65–9.CrossRefGoogle Scholar
7.King, DJ, Mills, PJ. Clozapine: The Holywell experience with the first 24 patients. Ir J Psych Med 1993; 10: 30–4.CrossRefGoogle Scholar
8.Rubin, M, Langa, A. Clozapine, mental retardation, and severe psychiatric illness: clinical response in the first year. Harvard Review of Psychiatry 1995: 293–4.Google Scholar
9.Haller, E, Binder, RL. Clozapine and seizures. Am J Psychiatry 1990; 147: 1069–71.Google ScholarPubMed
10.Kendell, RE, Zeally, AK. Companion to psychiatric studies. 5th ed. London: Churchill Livingstone, 1993: 634–5.Google Scholar
11.Deb, S, Hunter, D. Psychopathology of people with mental handicap and epilepsy, II: psychiatric illness. Br J Psychiatry 1991; 159: 826–30.CrossRefGoogle ScholarPubMed
12.Smith, K, Shah, A, Wright, K, Lewis, G. The prevalence and costs of psychiatric disorders and learning disabilities. Br J Psychiatry 1995; 166: 9–18.CrossRefGoogle ScholarPubMed